newsfilter
← Latest News
PR Newswire·

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...